This poster, presented at the 2022 San Antonio Breast Cancer Symposium (SABCS), illustrates challenges among oncology HCPs in optimally incorporating recommendations for the use of novel HER2-targeted therapies in the care of patients with HER2+ metastatic breast cancer.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.